Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Actemra for residual symptoms of schizophrenia
NCT02034474Phase 4Completed
- Sponsor
- New York State Psychiatric Institute
- Start
- Feb 2014
- Primary completion
- Feb 2017
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 4 trial of tocilizumab in schizophrenia, schizoaffective disorder, sponsored by New York State Psychiatric Institute. Started Feb 2014; status: completed.
02
Drugs
tocilizumab
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT02034474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02034474.